Compare Cytokinetics Inc (CYTK) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Fidelity National Information Servcs Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Fidelity National Information Servcs Inc trades at $42.9 (market cap $22.05B). The key difference: Fidelity National Information Servcs Inc is far larger — about 2.1× Cytokinetics Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | FIS | |
|---|---|---|
Market Cap | $10.63B | $22.05B |
Sector | Technology | Technology |
52-Week High | $87.26 | $72.77 |
52-Week Low | $34.31 | $37.72 |
Enterprise Value | $10.74B | $42.56B |
Dividend Yield | — | 4.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
FIS trades at $42.10, down 0.96% with bearish technical signals. The company shows improving fundamentals with Q2 2026 earnings beat and 5.3% revenue growth, though it lowered full-year guidance. Valuation appears attractive with P/E of 6.57 and P/S of 1.82. Recent expansion into APAC markets and treasury software recognition provide growth catalysts. Cash flow improved significantly from 2025's negative $1.35B to projected positive $188M for 2026.
FIS presents a mixed outlook with strong banking solutions growth offset by capital markets weakness. The 19% upside to consensus price target of $50.18 offers potential, but execution risks remain given the guidance reduction. Investors should weigh the attractive valuation against operational challenges in achieving sustained profitability improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
